Products Press Releases Partnering Careers Contact

Featured Post

Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada

January 13, 2026

August 29, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD

August 27, 2024

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients

July 24, 2024

Kye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada

July 2, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Chewable Tablets for the Treatment of Children With ADHD

October 26, 2023

Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada

September 25, 2023

Health Canada approves Quillivant® ER (extended release) oral suspension and chewable tablets for the treatment of ADHD.